ARO-ALK7 / Arrowhead Regional Medical Center - LARVOL DELTA

Study of ARO-ALK7 in Adult Volunteers With Obesity With and Without Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1/2 | N=90 | Not yet recruiting | Sponsor: Arrowhead Pharmaceuticals

New P1/2 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

ARO-ALK7, a RNAi Therapeutic Targeting Adipose ALK7 Expression for Obesity (ECO 2025) - No abstract available

Genetic Disorders • Obesity

Select ARO-ALK7 Preclinical Results (Businesswire) - "DIO mice treated with an ALK7 siRNA exhibit a 39% suppression in body weight gain relative to controls. Adipose ALK7 silencing reduced fat mass by 50% while preserving lean mass. Similar to INHBE silencing in hepatocytes, ALK7 silencing in adipocytes enhanced catecholamine sensitivity, increasing lipid mobilization and oxidation, which was not associated with liver steatosis. In fact, treated animals showed less liver fat accumulation relative to saline controls. In combination studies with tirzepatide, ALK7 siRNA enhanced the therapeutic benefits versus tirzepatide monotherapy, with additive effects on body weight and fat mass reduction while ameliorating the significant loss of lean mass associated with tirzepatide monotherapy...The company anticipates dosing in the ARO-ALK7 study will begin in the second quarter of 2025 with initial data from the single-ascending dose portion of the study possible by year end 2025."

Clinical data • New trial • Preclinical • Metabolic Disorders • Obesity

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity (Businesswire) - "The results were presented in a poster at the Keystone Symposia on Obesity and Adipose Tissue held February 23–26, 2025....Single subcutaneous doses of ARO-ALK7 led to dose-dependent and durable reductions in ALK7 mRNA in abdominal fat: Approximately 80% knockdown achieved at 0.3 mg/kg; Approximately 91% knockdown achieved at 1.5 mg/kg with 75% knockdown still observed after 12 weeks....ALK7 silencing in adipose tissue suppressed body weight gain and improved body composition: Body weight gain was suppressed by 40% relative to control; Approximately 50% reduction in fat mass with preservation of lean mass by DEXA imaging was observed in treated animals....Arrowhead received regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-ALK7 in New Zealand, which the company anticipates will begin dosing in the second quarter of 2025."

New P1/2 trial • Preclinical • Obesity